Efficacy of minodronate and denosumab for bone loss in patients with prostate cancer undergoing androgen deprivation therapy - the PROMADE (prevention of osteopenia with minodronate and denosumab) study

Department of Urology and Andrology, Kansai Medical University0 个研究点目标入组 102 人开始时间: 2015年9月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Bone metastasis 2)Castration resistance prostate cancer 3)hypocalcaemia Ca<8mg/dl 4)Androgen deprivation therapy>1 yr and Young Adult Mean>90% 5)Prior treatment with a bisphosphonate, RANKL, parathyroid hormone 6)Prior treatment with a glucocorticoids 7)Under treatment of tooth 8)A history of achalasia 9)Estimated glomerular filtration rate <35 ml/min 10)Liver function tests>1.5 times the upper limit of normal 11)Bilateral hip replacement 12)A history of metabolic bone disease (Paget disease, hyperparathyroidism, osteomalacia, untreated hypothyroidism) 13) The patients should be excluded ,Who have poor medical compliance, drug-induced allergy, etc.

发起方

Department of Urology and Andrology, Kansai Medical University